Aspire Biopharma Holdings, Inc., Announces Phase 1 Clinical Trial Initiation of its Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation
One clinical trial site activated
Patient enrollment expected in April
Trial designed to evaluate safety, pharmacokinetics and pharmacodynamics, of Aspire's sublingual aspirin product
Aspire anticipates releasing initial clinical data from trial at the end of the second quarter
Aspire intends to request 'fast track' approval on FDA application for its high-dose aspirin product
HUMACAO, PR AND NEW YORK, NY / ACCESS Newswire / April 9, 2025 / Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) ('Aspire' or the 'Company'), a developer of a multi-faceted patent-pending drug delivery technology, today announced initiation of its Phase 1 single- center clinical study of its lead therapeutic candidate, an oral transmucosal fast-acting high-dose aspirin formulation.
One clinical trial site has been activated with patient enrollment expected to total six to eight participants and begin during April.
Phase 1 Study Design
The objectives of this Phase 1 single dose clinical study are to evaluate the safety, pharmacokinetics and pharmacodynamics of Aspire's sublingual aspirin powder when administered orally in healthy adult volunteers. The Phase 1 clinical trial, which is being conducted in the United States, will compare the pharmacokinetic and pharmacodynamic characteristics of normal healthy adult volunteers administered a sublingual dose of 162.5 mg aspirin powder with control healthy subjects given 162.5 mg oral aspirin (approximately two 81 mg aspirin tablets). The primary outcome measure will be plasma acetylsalicylic acid (ASA) concentration versus time data (pre-dose and up to 24 hours post dose.)
This Phase 1 trial is expected to provide information required to select the optimal drug product formulation and inform the design of a second clinical trial, if needed, to support FDA approval. Following completion of this trial, Aspire plans to request a pre-IND meeting with the FDA in the second quarter of 2025 to finalize plans for continued development of high-dose aspirin leading to submission of a section 505(b)(2) NDA seeking approval to market the product for treatment of suspected acute myocardial infarction. An oral transmucosal acetylsalicylic acid (OTASA) product associated with rapid absorption and antiplatelet effects could provide important benefits for patients experiencing acute myocardial infarction where the benefits of aspirin in reducing the risk of vascular mortality are widely recognized and where every minute counts. In a large, multicenter study of aspirin, streptokinase, and the combination of aspirin and streptokinase in 17,187 patients with suspected acute MI, aspirin treatment produced a 23 percent reduction in the risk of vascular mortality. Aspirin was also shown to have an additional benefit in patients given a thrombolytic agent. (Source: https://pubmed.ncbi.nlm.nih.gov/2903874/)
Greater bioavailability of ASA, through the oral mucosa (avoiding first pass metabolism) could also potentially improve pharmacodynamic effects of aspirin for patients on repeated-dose aspirin regimens while limiting the potential for direct irritation to the gastric mucosa that could be associated with gastric bleeding.
'Initiation of this trial represents a critical step toward establishing additional clinical evidence for our novel therapeutic approach of targeted, rapid sublingual delivery of high dose aspirin directly to the bloodstream, which we believe could lead to better outcomes for patients,' said Kraig Higginson, Chief Executive Officer of Aspire. 'Direct delivery to the bloodstream and bypassing the gastrointestinal tract with our high dose aspirin product has potential for improved efficacy driven by more rapid absorption, while reducing or eliminating adverse reactions in the gastrointestinal tract for patients.'
Higginson continued, 'By evaluating the time to peak concentration of our aspirin formulation in this phase 1 trial, we expect to receive important insight into the pharmacokinetic and pharmacodynamic effects of our high dose sublingual aspirin, in addition to safety data. We anticipate faster absorption and increased drug levels when compared with conventional oral aspirin. We look forward to sharing preliminary data from the study towards the end of the second quarter.'
About High Dose Sublingual Aspirin
Aspire's lead product candidate, high dose sublingual aspirin, is a granular or powder formulation of a soluble, Ph neutral, fast-acting aspirin designed to address cardiology emergencies and pain management. Aspire believes the benefits of 'rapid absorption' aspirin include the potential to quickly address cardiac incidents much earlier in the 'golden hour' where intervention can save lives, allow high dose absorption for pain management including fast headache relief, post-surgery, cancer pain management, and general pain relief.
About the Aspire Targeted Oral Delivery Platform
Aspire's technology delivers a soluble, fast acting granular or powder form drug formulation which has been developed by using our patent-pending methodology, and 'trade secret' process. The technologies new mechanism of action allows for rapid sublingual absorption and entry into the bloodstream. The benefits of 'rapid absorption' are to provide nearly instant treatment impact and high dose absorption. The Company's patent-pending delivery system includes components specifically formulated to allow rapid sublingual absorption of drugs into the blood stream, thus by-passing the gastrointestinal tract, and potentially provide an improved treatment outcome.
About Aspire Biopharma, Inc.
Headquartered in Humacao, Puerto Rico, Aspire Biopharma has developed a disruptive technology through a Novel Soluble Formulation which addresses emergencies, drug efficacy, dosage management, and response time. For more information, please visit www.aspirebiolabs.com.
Safe Harbor Statement
Certain statements made in this communication are 'forward-looking statements' within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements may generally be identified by the use of words such as 'estimate,' 'projects,' 'expects,' 'anticipates,' 'forecasts,' 'plans,' 'intends,' 'believes,' 'seeks,' 'may,' 'will,' 'would,' 'should,' 'future,' 'propose,' 'potential,' 'target,' 'goal,' 'objective,' 'outlook' and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. These forward-looking statements include, but are not limited to, statements regarding the financial position, business strategy and the plans and objectives of management for future operations. These statements are based on various assumptions, whether or not identified in this communication, and on the current expectations of Aspire's management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as and must not be relied on by any investor as a guarantee, an assurance, a prediction or a definitive statement of fact or probability. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside the control of the parties, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.
Aspire Biopharma Holdings, Inc.
Contact
TraDigital IR
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
26 minutes ago
- Business Insider
Sarepta suspends non-ambulatory Elevidys shipments after second death
Sarepta (SRPT) Therapeutics provided a safety update regarding Elevidys, an FDA approved gene therapy for patients with Duchenne muscular dystrophy. The company announced a second reported case of acute liver failure resulting in death. The cases of ALF to date have both occurred in non-ambulatory individuals with Duchenne. Sarepta is temporarily suspending shipments of Elevidys for non-ambulatory patients while an enhanced immunosuppressive regimen is evaluated, discussed with regulatory bodies, and put in place. For ambulatory patients, no treatment changes are being proposed and the current practice of administering corticosteroids before and after Elevidys infusion, along with post-treatment monitoring, remains the same. Sarepta has also voluntarily paused dosing in the ENVISION clinical study. FDA concurs with this action, the company said. 'The pause will allow for the evaluation of a protocol amendment to incorporate an enhanced immunosuppressive regimen for the non-ambulatory patient cohort and incorporate any additional feedback from the FDA. Regulatory alignment is needed before screening and dosing in ENVISION may resume,' Sarepta added. The company is working to immediately convene an independent group of leading experts in Duchenne and liver health to consider an enhanced immunosuppression regimen for Elevidys.
Yahoo
an hour ago
- Yahoo
Veteran analyst sends surprising message on stocks, bonds, and gold
Veteran analyst sends surprising message on stocks, bonds, and gold originally appeared on TheStreet. The stock market rally has been impressive. Since President Donald Trump paused most reciprocal tariffs on April 9, only days after announcing them, stocks have soared. The S&P 500 has gained about 20%, while the tech-stock heavy Nasdaq Composite is up 27%. Those returns in such a short span significantly outpace the average 10% annual return for stocks since 1928. Stocks haven't been the only winner. Gold has also notched impressive returns this year. The yellow metal has rallied 30% in 2025 as investors have sought to insulate risk amid growing economic concerns surrounding debt and the impact of tariffs on one big disappointment this year: Treasury bonds. They've tumbled, sending bond yields soaring, as global investors have soured on financing America's insatiable appetite for spending. The market action has captured the attention of many, including veteran commodities and futures analyst Carley Garner. Garner has been professionally navigating these markets for 20 years, and her track record includes accurately predicting the stock rally in 2023 and last year's decline in oil prices. Garner updated her outlook on stocks, gold, and bonds, and her takeaway may surprise you. Stocks' rally since the lows in early April likely surprised many, given significant economic risks remain. While inflation has retreated below 3% from over 8% in 2022, price increases over the past years have cash-strapped consumers, causing them to shift spending from discretionary purchases to problem has been compounded by an uptick in unemployment, which has increased to 4.2% from 3.4% in 2023, partly due to higher interest rates designed to crimp inflation. According to Challenger, Gray, & Christmas, U.S. companies have laid off 696,309 workers this year through May, up 80% from one year ago. The situation isn't likely to get much better for workers. While Trump paused many reciprocal tariffs in April, key tariffs remain, including a 25% tariff on Canada and Mexico and autos, a 10% tariff on all imports, and 30% tariff on China (total tariffs on China, including those put in place during President Trump's first term exceed 50%). The remaining tariffs, and potential for more after the 90-day pause expires, could fuel inflation later this year, particularly in retail, which sources everything from clothing to electronics from overseas. The risk of inflation alongside job losses suggests America could go headlong into a period of stagflation or recession. Despite those risks, the S&P 500 and Nasdaq Composite have notched remarkable gains. Investors who quickly sold amid tariff announcements earlier this year have been left behind, and as a result, they're buying every dip to regain their exposure. One major exception? Warren Buffett. The Oracle of Omaha has increased Berkshire Hathaway's cash position, choosing to collect guaranteed fixed income from T-bills rather than leap back into the stock market amid the uncertainty. Exiting the first quarter, Warren Buffett's cash stockpile eclipsed $347 billion, a record, and more than double the levels exiting 2023. The rallies in stocks and gold may continue, but like Buffett, Carley Garner doesn't see the risk-to-reward as overly compelling in stocks. She's also become bearish on gold relative to bonds, given that gold has moved significantly higher and, unlike bonds, doesn't pay dividends. "While I believe the S&P 500 can easily reach 6300 to 6400, the downside risk might be outsized relative to the potential reward," wrote Garner on TheStreet Pro. "Since 1928, the S&P 500 has returned an average annual rate of 10%; however, in recent years, the average return has been abnormally high, at approximately 14%. There is a good chance that, like the dot-com era, we have pulled forward gains and could be on the verge of a 'returnless' market in the coming years." Garner points to a key measure favored by Warren Buffett regarding stock market valuation as evidence that stocks are over their skis. More Experts: Fed official sends strong message about interest-rate cuts Billionaire fund manager sends surprising message on trade deficit Hedge-fund manager sees U.S. becoming Greece "The Warren Buffett Indicator measures the total stock market value vs. the GDP," wrote Garner. "Since 1950, the stock market has only been this overstretched a few other times. Not surprisingly, the dot-com bubble was one of those times. Historically, this indicator has not been the time to hit the gas on risk assets. It has been the opposite." The arguable overvaluation of stocks could mean the risk of a reckoning is high enough to concentrate on other assets. However, gold may not be the best bet, given it's already made a big move higher. Instead, it's Treasury bonds that Garner believes offer the best chance for upside. "There is only one [of these assets] near a two-decade low in valuation: Treasuries," writes Garner. "Except for some forms of real estate, it is the only asset that yields an attractive income stream. Lastly, Treasuries are the least risky asset class in the world but the market is treating the securities as anything but." Garner points out that people were flocking to own bonds with paltry yields only five years ago. Now, they're shunning yields near 4.5%. Many are hesitant to own bonds despite the high yields, fearing that bonds will continue to drop, sending yields even higher, as the U.S. debt load rises. While it's true that lower bond values could mean short-term losses, Garner views the risk of a U.S. default as unlikely, suggesting that those holding Treasuries to maturity will be fine, and pocket healthy income along the way. "Historically, there have been two other instances in history when stocks were as overvalued as they are now relative to bonds. Or, alternatively, bonds were this undervalued relative to stocks," wrote Garner. "Such opportunities have only arisen once every two decades, and they have proven to be significant inflection points in both stocks (the beginning of prolonged underperformance) and bonds (the start of a period of capital gains to enhance interest earned). This metric has been similarly favoring bonds since the initial collapse in 2023, so instant satisfaction shouldn't be expected, but patience will likely pay off."Veteran analyst sends surprising message on stocks, bonds, and gold first appeared on TheStreet on Jun 15, 2025 This story was originally reported by TheStreet on Jun 15, 2025, where it first appeared. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Duolingo Stock Is Overvalued, According to Wall Street. Time to Sell?
Duolingo stock has surged to levels that do not make sense for some investors. The underlying business is performing extraordinarily well, and management isn't resting on its laurels. 10 stocks we like better than Duolingo › After jumping a hefty 43% in 2024, shares of language-learning app Duolingo (NASDAQ: DUOL) are up another 47% so far in 2025. And according to select Wall Street analysts, the stock has simply climbed too far, too quickly. Stock research platform TipRanks is currently tracking 15 analysts who cover Duolingo stock. Of these analysts, none recommend selling the stock, but their average price target is $476 per share, slightly below where Duolingo is trading as of this writing. In other words, Duolingo stock trades above what these professionals believe it's worth. It's obviously time to sell, right? Well, it's more complicated than that. Most Wall Street price targets only take into account the next 12 to 18 months. But for those who want to consistently do well investing in stocks, a long-term view is beneficial. Investors who hold stocks for five years or more tend to outperform their less patient counterparts. But the buy-and-hold philosophy can't be used indiscriminately. To the contrary, the underlying business still needs to do well during the holding period -- buying and holding businesses with declining fundamentals is still a losing proposition. Therefore, that's the first thing to consider with Duolingo: Is this business poised to do well over the next five years? Duolingo is known for its language-learning courses, and that business is absolutely booming. Nearly 47 million people used the platform every single day during the first quarter of 2025, and 10 million people pay for a subscription that offers extra perks, a whopping 40% increase from the prior-year period. Duolingo's management attributes its success to a variety of factors, but here are two big ones. First, the company does a lot of A/B testing, constantly making changes based on what's working with its users. Second, it also incorporates a lot of game-like elements into the learning process, keeping users motivated and engaged. Now, Duolingo is taking its language expertise and broadening its focus to other verticals, such as math, music, chess, and more. There's no limit to what the company can do when it comes to launching courses and programs, which greatly increase its market opportunity. For what it's worth, companies that can easily expand their market opportunity with related products and services often do well over the long term. Revenue growth is important for creating shareholder value, and it's easier to grow the top line when the opportunity is getting bigger. Since the start of 2022, Duolingo has averaged over 40% quarterly revenue growth, meaning revenue is doubling about every two years. That's extraordinary. Now, generative artificial intelligence (AI) is helping Duolingo develop new products faster than ever. It launched nearly 150 new language courses in Q1 alone. For some investors, this is a good thing -- the company can expand and grow even more quickly. For others, however, this technology presents a risk to Duolingo. Generative AI could also make it easier for other companies to offer competing services. This two-sided risk should be acknowledged, even as Duolingo's business is thriving. I believe it's safe to say that, trading at nearly 30 times its sales, Duolingo stock doesn't look like a bargain at the moment. The chart below shows that a large portion of the stock's gains this year are due to an expanding valuation multiple, which should always give potential new investors pause. The reality is that as Duolingo gets bigger, its growth will likely slow. But even if you assume it sustains a 40% growth rate, the company would generate $4.0 billion in annual revenue by 2029. With a current market capitalization of $21.9 billion, Duolingo still trades at 5.5 times that 2029 sales forecast. That premium leaves investors with the difficult job of weighing a growing business with sound fundamentals and a large market opportunity against a share price that's increasingly hard to justify. None of this is to say existing Duolingo shareholders should be selling out of their positions. Personally, I'm waiting on the sidelines for a price that makes sense to me before buying the stock. Those who decide to buy now are best served by maintaining a long-term perspective. Before you buy stock in Duolingo, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Duolingo wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $653,702!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $870,207!* Now, it's worth noting Stock Advisor's total average return is 988% — a market-crushing outperformance compared to 172% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 9, 2025 Jon Quast has no position in any of the stocks mentioned. The Motley Fool recommends Duolingo. The Motley Fool has a disclosure policy. Duolingo Stock Is Overvalued, According to Wall Street. Time to Sell? was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
